The GLP-1 agonists market therefore continues to tilt toward long-acting injectables, anchoring semaglutide and tirzepatide at the forefront while relegating older daily products to niche status
Phase 2 trial data (Jastreboff et al., NEJM, 2023) demonstrated substantial weight reduction participants lost a mean of approximately 24% of body weight over 48 weeks at the highest doses alongside improvements in cardiometabolic markers
The condition exists in two primary forms: metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD), which affects individuals who consume little to no alcohol, and alcoholic fatty liver disease
Nausea was reported in a significant proportion of participants, particularly during the dose-escalation period (Jastreboff et al., 2023)
Discover WHEN There's Hope on the Horizon The medications we supply are intended for patients with a body mass index (BMI) of 27 or higher, who have at least one weight-related condition, or for patients with a BMI of 30 or higher
